1. Home
  2. Team
  3. Thomas Casdagli

Thomas joined MVM in 2002. Before joining MVM, he worked at PricewaterhouseCoopers’ Private Equity and Venture Capital practice. Thomas has an MBioch in Molecular and Cellular Biochemistry from Oxford University.

Thomas is a member of the boards of eXmoor Pharma Concepts Ltd, icotec AG, and observer at Avanzanite Bioscience BV. He was previously a director of Valneva SE (EPA: VLA), Alliance Pharma plc (AIM:APH), Lombard Medical Technologies plc (NASDAQ:EVAR), Heptares Ltd (acquired by Sosei Group Corporation), Avantium BV (AMS:AVTX), Onbone Oy, eZono AG, and Xention Pharma.

Latest news

MVM invests in Neurent Medical
February 11, 2026
Newton Expands Access to Neurolens and Sequel Technologies with ABB Labs
January 13, 2026
Proverum receives FDA approval for the ProVee System – the first of a new generation of prostatic urethral stents for treatment of BPH
December 9, 2025
MVM invests in Avanzanite
November 18, 2025
GT Medical Technologies’ trial demonstrates a >50% reduction in the risk of brain tumor recurrence or death compared with standard of care
October 21, 2025
Boston Scientific agrees to acquire Nalu Medical
October 17, 2025
MVM invests in Proverum
August 25, 2025
Paratek Pharmaceuticals completes acquisition of Optinose
May 21, 2025
Zimmer Biomet completes acquisition of Paragon 28
April 21, 2025
GT Medical Technologies Raises $37 Million in Series D to Advance the Expansion of GammaTile® in the U.S. for Patients with Operable Brain Tumors
January 16, 2025
View all